BMS & AstraZeneca Club Together For Amylin Acquisition

BMI View: Bristol-Myers Squibb (BMS) has paid a lot for Amylin and its GLP-1 products, the deal makes sense for BMS and its diabetes ally AstraZeneca, but the prevailing risks stem from the increasing level of competition within the GLP-1 arena. Acquired Amylin may have got to market first with an extended-release, once-weekly diabetes drug, but will soon face competition from rival once-weeklies from Novo Nordisk, GlaxoSmithKline (GSK), Sanofi and Amylin's ex-partner Eli Lilly. The BMS/AstraZeneca's diabetes alliance makes this deal more financially agreeable for BMS and may have allowed it to out bid other competitors.

To read the full article, please choose one of the following options: